In a little over the past year, several clinical trials have evaluated new drugs in patients with metastatic colorectal cancer and gastric cancer. Furthermore, genomics studies that attempted to unravel the molecular characteristics of colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer
Cell Death & Disease Open Access 09 July 2020
-
STRA6 exerts oncogenic role in gastric tumorigenesis by acting as a crucial target of miR-873
Journal of Experimental & Clinical Cancer Research Open Access 06 November 2019
-
Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target
Scientific Reports Open Access 10 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065–1075 (2014).
Maier, R. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909–1919 (2015).
Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013).
Tabernero, J. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16, 937–948 (2015).
Dienstmann, R. et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 5, 1–12 (2015).
Lida, M. et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 15, 1196–1206 (2013).
Le, D. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Fuchs, C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro−oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014).
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro−oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.V.C. has received research grants from Amgen, Bayer, Boehringer, Celgene, Ipsen, Lilly, Merck Serono, Novartis, Roche, and Sanofi. M.D. is on the advisory board and has attended symposia for Amgen, Celgene, Lilly, Merck, Novartis, and Roche. M.D.'s wife is employed by Sandoz (Novartis group).
Rights and permissions
About this article
Cite this article
Van Cutsem, E., Ducreux, M. The development of new agents and molecular classifications. Nat Rev Clin Oncol 13, 69–70 (2016). https://doi.org/10.1038/nrclinonc.2015.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.217
This article is cited by
-
SOX2-Induced Linc-ROR Upregulation Inhibits Gastric Carcinoma Cell Proliferation and Metastasis Via the miR-580-3p/ANXA10 Pathway
Biochemical Genetics (2023)
-
Knockdown of Long Non-coding RNA LINC00200 Inhibits Gastric Cancer Progression by Regulating miR-143-3p/SERPINE1 Axis
Digestive Diseases and Sciences (2021)
-
Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer
Cell Death & Disease (2020)
-
STRA6 exerts oncogenic role in gastric tumorigenesis by acting as a crucial target of miR-873
Journal of Experimental & Clinical Cancer Research (2019)
-
Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target
Scientific Reports (2018)